ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable
2.12.2025 11:00:00 CET | Business Wire | Press release
Study by EU regulatory expert Prof. Andrea Minto and ThetaRay VP Regulatory Affairs Yaron Hazan finds legacy AML tools unfit for Europe’s new regulatory era
ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/

Next Generation AML Solutions
The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artificial Intelligence Act will reshape compliance across the region.
Co-authored by Prof. Andrea Minto, a leading authority on EU financial regulation at Ca’ Foscari University of Venice and the University of Stavanger, and Yaron Hazan, ThetaRay’s Vice President of Regulatory Affairs, Advisory board member at the AI APAC Institute and former Head of Compliance at HSBC Israel, the study blends academic rigor with supervisory and operational expertise rarely found in a single publication.
The report finds that despite rising budgets and stronger enforcement, Europe’s AML framework continues to underperform:
- The FATF reports that 97% of 120 assessed countries show only low to moderate effectiveness in preventing money laundering and terrorist financing.
- FIUs across Europe report extremely low intelligence yield: the Netherlands identified <3.5% of 3.48 million 2024 reports as suspicious, while France’s Tracfin reports only ~5% actionable SARs.
- Germany’s FIU data shows that only 15% of SARs are investigated by law enforcement, with 95% of forwarded cases ending without prosecution.
- One operational risk study found that rules-based detection scenarios produced reporting in just 2% of cases.
According to the study, the global AML system suffers from persistent structural inefficiencies, high false-positive rates, and poor conversion from alerts to meaningful intelligence, the result of legacy rule-based systems that generate low-quality alerts, rely on siloed architectures, and lack the cross-border visibility required to detect modern networked financial crime.
“The data is clear: Europe’s AML system is no longer keeping pace with financial complexity,” said Yaron Hazan, Vice President of Regulatory Affairs at ThetaRay. “For years, institutions have been trapped in a cycle of rule tuning, manual investigations, and defensive reporting, without materially improving outcomes. Under the new regulatory regime, failing to adopt AI will become a compliance vulnerability.”
The report highlights how the EU’s two major regulatory initiatives, the AML Package and the AI Act, together represent the most consequential shift in AML expectations in decades. The AML Package strengthens due diligence obligations, expands governance requirements, and establishes a new EU-level Anti-Money Laundering Authority (AMLA), harmonizing obligations across Member States. At the same time, the AI Act classifies transaction monitoring and sanctions screening as “high-risk” uses of AI, imposing strict requirements on transparency, human oversight, data governance, and model lifecycle management.
The authors also highlight heightened vulnerabilities in correspondent banking and crypto-asset flows, where traditional rule engines struggle to detect hidden network behaviour across complex cross-border transaction chains. The study further identifies growing friction between the AML Regulation (AMLR) and GDPR data processing constraints, warning that without clearer guidance, institutions could face overlapping regulatory and legal risks.
“Europe’s new AML framework fundamentally raises the standard for what effective compliance means,” said Andrea Minto, Professor of Law and Regulation of Financial Markets at Ca’ Foscari University of Venice and the University of Stavanger. “The AML Package and the AI Act make clear that the integration of AI into customer due diligence and AML monitoring is inevitable. Financial institutions must now prepare for a world in which technological capability and legal obligation are inseparable.”
The report ultimately calls for a fundamental shift from volume-driven alerting to intelligence-led detection, emphasizing hybrid human-AI oversight, robust data governance aligned with the AI Act, transparent and explainable models, integrated customer and transaction screening workflows.
Read the report here.
About ThetaRay
ThetaRay harnesses the power of Cognitive AI for financial crime compliance, enabling financial institutions to precisely identify legitimate customers while flagging bad actors. The SaaS solutions overcome the limitations of traditional rule-based systems by shortening long implementation lifecycles, enabling efficient, risk-aware compliance operations. By transforming compliance from a regulatory obligation into a driver of growth, ThetaRay allows institutions to scale faster and expand confidently into new markets. By uncovering hidden criminal networks and delivering actionable insights, ThetaRay empowers organizations to combat evolving threats, maintain positive regulator relationships, and enhance customer experiences. Implemented at some of the world’s leading financial institutions including Santander, Clear Bank, Mashreq Bank, Payoneer, Onafriq and Travelex, ThetaRay helps financial institutions thrive, fostering trust and confidence across the global financial ecosystem. For more information, visit www.thetaray.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202058684/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom